Thus, randomized controlled trials with larger sample sizes and longer follow-up time are necessary in the future to continue to validate the efficacy and safety of PLD plus docetaxel and trastuzumab for the neoadjuvant treatment of patients with HER2-positive BC. Here, ERBB2 is linked to breast cancer.